🔗 Share this article

This year's Nobel Prize in medical science was granted for transformative findings that illuminate how the body's defense network targets dangerous infections while sparing the healthy tissues.

Three esteemed scientists—from Japan Shimon Sakaguchi and US scientists Dr. Brunkow and Dr. Ramsdell—share this accolade.

The work uncovered unique "sentinels" within the defense system that eliminate malfunctioning defense cells that could harming the organism.

The discoveries are now paving the way for new therapies for autoimmune diseases and cancer.

The laureates will share a monetary award valued at 11 million Swedish kronor.

Crucial Findings

"The research has been decisive for understanding how the body's defenses functions and the reason we don't all develop severe autoimmune diseases," commented the head of the Nobel Committee.

The trio's studies address a fundamental mystery: How does the immune system defend us from countless infections while keeping our own tissues intact?

The body's protection system uses white blood cells that scan for signs of infection, including viruses and germs it has never encountered.

These cells utilize sensors—known as receptors—that are generated randomly in a vast number of combinations.

This gives the immune system the capacity to combat a broad range of invaders, but the unpredictability of the process unavoidably creates white blood cells that may attack the body.

Security Guards of the Body

Researchers previously understood that some of these harmful defense cells were eliminated in the immune organ—where immune cells mature.

The latest Nobel Prize recognizes the identification of regulatory T-cells—described as the immune system's "security guards"—which travel through the body to disarm other immune cells that attack the healthy cells.

It is known that this process fails in autoimmune diseases such as juvenile diabetes, MS, and rheumatoid arthritis.

The prize committee stated, "The discoveries have established a new field of investigation and accelerated the development of innovative treatments, for example for cancer and immune disorders."

In malignancies, regulatory T-cells block the body from fighting the growth, so research are aimed at reducing their quantity.

In self-attack disorders, trials are exploring boosting regulatory T-cells so the organism is not under attack. A similar approach could also be useful in minimizing the risks of organ transplant failure.

Innovative Studies

Prof Sakaguchi, from a Japanese institution, performed tests on mice that had their thymus extracted, causing autoimmune disease.

He showed that injecting defense cells from other animals could prevent the disease—implying there was a system for blocking defenders from attacking the host.

Dr. Brunkow, affiliated with the a research center in Seattle, and Fred Ramsdell, now at Sonoma Biotherapeutics in San Francisco, were studying an inherited autoimmune disease in mice and humans that led to the identification of a genetic factor vital for the way regulatory T-cells operate.

"Their pioneering research has uncovered how the body's defenses is controlled by regulatory T cells, stopping it from accidentally attacking the healthy cells," commented a leading biological science expert.

"The work is a remarkable illustration of how basic physiological study can have far-reaching implications for human health."